MOTS-c (Mitochondrial Open reading frame of the twelve S rRNA-c) is a 16-amino-acid peptide encoded inside the mitochondrial genome itself, specifically within the 12S ribosomal RNA gene. That makes it one of only a handful of bioactive peptides with a mitochondrial rather than nuclear genetic origin. The discovery came from Changhan David Lee's group at USC in a 2015 Cell Metabolism paper (Lee et al., Cell Metabolism, 2015), and it forced a real conceptual reset: mitochondria weren't just power plants, they were endocrine signalling centres putting out peptides that regulate whole-body metabolism.
Key Takeaways
- —MOTS-c is a 16-aa peptide encoded in the mitochondrial 12S rRNA gene — not the nuclear genome — making it one of only a few known mitochondria-derived bioactive peptides (Lee et al., Cell Metabolism, 2015).
- —Intraperitoneal MOTS-c in high-fat diet mice reduced diet-induced obesity by 40% and restored insulin sensitivity, with the effect tracing back to AMPK activation in skeletal muscle.
- —Under metabolic stress MOTS-c moves into the nucleus, binds AMPK, and turns on genes for glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
- —Circulating MOTS-c drops hard with age — levels in 50–65 year-olds run roughly 40–60% lower than in 20–30 year-olds, which lines up neatly with age-related metabolic decline.
MOTS-c broke the old "mitochondria are passive energy factories" model. Mitochondria are basically endosymbiotic bacteria that got absorbed into eukaryotic cells about 2 billion years ago, and they kept their own circular genome. In humans that genome carries 37 genes — 13 protein-coding, 22 tRNAs, 2 rRNAs. MOTS-c is hidden inside one of those rRNA genes (12S rRNA), in a region nobody had flagged as protein-coding.
Lee's team used computational genomics to find the open reading frame inside 12S rRNA, synthesised the peptide, and showed it was actually expressed in liver, skeletal muscle, and plasma (Lee et al., Cell Metabolism, 2015). Because it circulates in the blood, it acts as a hormone — the mitochondria are using it to broadcast their metabolic status to distant tissues.
The mitochondrial origin isn't trivia, it's functionally important. Mitochondria replicate independently of nuclear DNA and accumulate mutations at roughly 10× the rate, so MOTS-c levels vary by mitochondrial haplotype. Published data shows people with longevity-associated haplogroups (haplogroup D4 in Japanese centenarian cohorts is the cleanest example) carry higher MOTS-c expression. That ties MOTS-c to the genetics of exceptional longevity in a way no nuclear-encoded peptide can match.
AMPK activation: AMPK is the master energy sensor in eukaryotic cells. It flips on when the AMP/ATP ratio rises (cell is running low on energy), and the response is the classic catabolic programme — burn fat, pull in glucose, shut down lipid synthesis and gluconeogenesis. MOTS-c activates AMPK in skeletal muscle without the cell actually having to be energy-depleted. Functionally it mimics the metabolic signal of exercise, which is where the "exercise mimetic" framing comes from.
Nuclear translocation under stress: When the cell hits metabolic stress, MOTS-c moves out of the cytoplasm and into the nucleus, where it directly binds and activates the AMPK promoter and interacts with ARE (antioxidant response element) binding proteins. A circulating peptide acting as a transcription factor in the nucleus is mechanistically weird — most hormones don't do that.
AICAR pathway convergence: MOTS-c also blocks the folate cycle in one-carbon metabolism, which causes AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) to pile up. AICAR is a well-known endogenous AMPK activator (Lee et al., Cell Metabolism, 2015). So you get a second, indirect route to AMPK on top of the direct one.
Glucose and fatty acid metabolism: MOTS-c pushes GLUT4 to the plasma membrane (more glucose uptake) and upregulates CPT1 plus other genes that govern mitochondrial fatty acid oxidation. Net effect is improved metabolic flexibility — the cell can switch fuels more efficiently.
The Kim/Lee 2015 Cell Metabolism paper is still the foundation (Lee et al., Cell Metabolism, 2015). The key findings:
Follow-up work from 2016–2023 extended the picture:
Human dosing for MOTS-c is extrapolated from mouse data (allometric scaling) plus early clinical use, not from published human RCTs. Lee's 2015 mouse protocol was 0.5 mg/kg/day intraperitoneally. Run that through the standard 12:1 mouse-to-human conversion and you land in the 2–5 mg/day range for humans.
| Parameter | Research Protocol Range |
|---|---|
| Dose | 5–10 mg per injection |
| Route | Subcutaneous |
| Frequency | 1–3× per week |
| Cycle | 4–8 weeks on, 4 weeks off |
| Reconstitution | Bacteriostatic water (standard) |
There's no published human PK data and the plasma half-life isn't well characterised, so these protocols are provisional. In practice most people start at the bottom of the range — 5 mg subq pin 2× weekly with BAC water — and read the response off subjective energy and performance, plus metabolic markers (fasting glucose, HbA1c) when they can pull labs. N=1 is the rule here, not the exception. Anecdotally, the most common reported effect is a "second mountain of energy in the afternoon" rather than the morning jolt people associate with stims.
MOTS-c is endogenous — encoded in your own mitochondrial genome and produced naturally in skeletal muscle, liver, and other tissues. That's a real baseline safety argument: you're not introducing a foreign agent, you're topping up something that's already in you and declining with age.
Animal studies report no toxicity at therapeutic doses. Human adverse event data is thin — case reports and small clinical series, no systematic safety study published yet. The main thing people report is injection site reactions from the subq pin. From what people report, this sits in the same neighbourhood as other mitochondrial peptides like NAD+ and Humanin: low acute risk, long-term human data still missing.
MOTS-c is one of the most scientifically novel compounds in the research peptide space and one of the most commonly misrepresented on vendor sites. The Next Pep peptide library covers the full 16-aa mitochondrially-encoded profile: AMPK activation mechanism, the Lee et al. 2015 Cell Metabolism HFD mouse data, the age-related decline curve, and the insulin sensitivity and sarcopenia evidence. All sourced against primary literature, not vendor copy.
Use the comparison tool to put MOTS-c next to other metabolic or longevity peptides — mechanism, evidence quality, and access route in one view. The dosing calculator handles reconstitution for SC protocols: enter your vial concentration and it returns exact draw volume and syringe units. Research the compound on Next Pep before you evaluate any supplier — COA, HPLC, third-party tested, the usual checks.
Most exercise mimetics (AICAR, GW501516) are small molecules hitting one specific pathway. MOTS-c is an endogenous peptide that activates AMPK through the route the body actually uses — it's the native signal mitochondria send out to communicate metabolic status. Plus its mitochondrial genetic origin links it to real longevity genetics in a way small-molecule mimetics can't claim.
No. The "exercise mimetic" label points to mechanistic overlap at the molecular level (AMPK activation, GLUT4 upregulation, mitochondrial biogenesis genes), not a full clone of what exercise does. Exercise gives you mechanical loading, cardiovascular adaptation, and a hormonal cascade MOTS-c can't reproduce. The realistic use case is sharpening metabolic efficiency and insulin sensitivity, especially in older people or anyone with metabolic dysfunction.
Endogenous MOTS-c drops with age — published data has 50–65 year-olds running 40–60% lower than young adults (Reynolds et al., Aging Cell, 2021). That decline tracks with age-related insulin resistance, sarcopenia, and reduced mitochondrial biogenesis. The "restore MOTS-c, reverse some of the metabolic age effects" hypothesis is mechanistically reasonable and the animal data backs it, but human intervention data isn't there yet.
Both are mitochondria-derived peptides (MDPs) encoded in the 12S rRNA gene. Humanin came first (2003) and its main characterised effects are neuroprotection (blocking amyloid beta toxicity) and cytoprotection (Hashimoto et al., PNAS, 2001). MOTS-c is the metabolic one — AMPK activation, insulin sensitisation, mitochondrial biogenesis. They run on overlapping but distinct pathways, and people sometimes stack them in longevity protocols alongside NAD+ for the full mitochondrial reset angle.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.